Chemical compound
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H21NO |
Molar mass | 291.394 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
JWH-030 is a research chemical which is a cannabinoid receptor agonist.[1] It has analgesic effects and is used in scientific research.[2] It is a partial agonist at CB1 receptors, with a Ki of 87 nM, making it roughly half the potency of THC.[3] It was discovered and named after John W. Huffman.
In the United States, CB1 receptor agonists of the 3-(1-naphthoyl)pyrrole class such as JWH-030 are Schedule I Controlled Substances.[4]
See also
[edit]References
[edit]- ^ Lainton JA, Huffman JW, Martin BR, Compton DR (February 1995). "1-Alkyl-3-(1-naphthoyl) pyrroles: A new class of cannabinoid". Tetrahedron Letters. 36 (9): 1401–4. doi:10.1016/0040-4039(95)00016-6.
- ^ Pertwee RG, Griffin G, Lainton JA, Huffman JW (September 1995). "Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens". European Journal of Pharmacology. 284 (3): 241–7. doi:10.1016/0014-2999(95)00318-f. PMID 8666005.
- ^ Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME (May 1998). "Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes". The Journal of Pharmacology and Experimental Therapeutics. 285 (2): 553–60. PMID 9580597.
- ^ 21 U.S.C. § 812: Schedules of controlled substances
Psychedelics (5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dissociatives (NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deliriants (mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Others |
|